In this episode, Anna F. Farago, MD, PhD, and Taofeek K. Owonikoko, MD, PhD, answer questions focused on the topic of current and evolving use of immunotherapy in patients with advanced small-cell lung cancer with topics including:Selecting between atezolizumab and durvalumab in the frontline settingIntegration of lurbinectedin, a novel anticancer drug that was recently approved for the treatment of relapsed SCLC after platinum-based chemotherapy, into patient careWhich patients should receive salvage therapy with an immune checkpoint inhibitor in the third-line settingManagement of brain metastases in patients with advanced SCLCPresenters:Anna F. Farago, MD, PhDAssistant Professor of MedicineDepartment of MedicineHarvard Medical SchoolAssistant in MedicineDivision of Hematology/OncologyDepartment of MedicineMassachusetts General HospitalBoston, Massachusetts Taofeek K. Owonikoko, MD, PhDProfessorDepartment of Hematology and Medical OncologyCo-Leader, Thoracic OncologyEmory UniversityAtlanta, GeorgiaContent based on an online CME program supported by educational grants from Genentech, a member of the Roche Group, and Merck Sharp & Dohme Corp. Link to full program, including associated downloadable slidesets: https://bit.ly/3aTzthZ

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related